Pezadeftide
Hexima is conducting a phase IIb clinical trial of its lead antifungal molecule, pezadeftide (previously HXP124), as a potential topical treatment for fungal nail infections (onychomycosis).
Investor Webinar 29 July 2021
Latest NailMail Newsletter
Hexima is holding an Investor Webinar on 29 July 2021 at 9am (AEST) to provide an insight into our presentation at the upcoming APMA conference and an update on the company’s activities.
NailMail is Hexima’s regular quarterly newsletter to shareholders, investors and interested parties.
Investor Webinar 29 July 2021
Hexima is holding an Investor Webinar on 29 July 2021 at 9am (AEST) to provide an insight into our presentation at the upcoming APMA conference and an update on the company’s activities.
Latest NailMail Newsletter
NailMail is Hexima’s regular quarterly newsletter to shareholders, investors and interested parties.
External Links
Take a look at these useful links to learn more about our industry.
